2-Methoxyestradiol (2ME2) is a drug that prevents the formation of new blood vessels that tumors need in order to grow (angiogenesis). It has undergone Phase 1 clinical trials against breast cancers and preclinical studies suggest that 2ME2 could also be effective against inflammatory diseases such as rheumatoid arthritis.
For the treatment of breast cancer and inflammatory diseases such as rheumatoid arthritis.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.